Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec and Roche expand chemistry deal
Evotec OAI has a long-standing relationship with Roche. In 2004, the companies signed a substantial medicinal chemistry agreement, supporting four Roche sites in the design and synthesis of
Evotec OAI has a long-standing relationship with Roche. In 2004, the companies signed a substantial medicinal chemistry agreement, supporting four Roche sites in the design and synthesis of
Perlegen intends to apply its leading whole genome pharmacogenomics technology to improve upon the demonstrated efficacy and safety profile of MCC-555 (a peroxisome proliferator activated receptor, or PPAR,
Under the agreement, Alnylam will provide Benitec and its licensees an option to non-exclusively license Alnylam-controlled intellectual property (IP) in the field of expressed RNA interference (RNAi): targeted
These findings are important because several commonly prescribed anti-epileptic drugs (AEDs) may reduce the effectiveness of oral contraceptives, a potentially serious drug interaction for some women with epilepsy.
Vaccinia immune globulin (VIGIV) is used to treat rare serious reactions that sometimes occur with smallpox vaccination. The hyperimmune plasma will be supplied by Life Sera, an Atlanta-based
Two-year data from a phase III monotherapy trial, named AFFIRM, showed that treatment with Tsyabri (natalizumab) led to a significant reduction in disability progression, the rate of clinical
Osmotics Pharma Inc (OPI) is an emerging specialty pharmaceutical company focused on developing prescription products for the treatment of various dermatological disorders, antibiotic-resistant strains of bacteria and certain
The two companies had intended to submit a supplemental biologics license application (sBLA) for Erbitux (cetuximab) as a single agent and in combination with radiation in squamous cell
Lactin-V, a capsule containing a natural human bacterial organism, will be studied in a total of eight centers for recurrent urinary tract infection (RUTI) and recurrent bacterial vaginosis
Provectus is preparing the FDA filing to commence the trials and expects to begin clinical studies for psoriasis in late 2005 and eczema in 2006. The company has